Raltegravir: First in class HIV integrase inhibitor

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 493-500

  Temesgen, Zelalem ^a   Siraj, Dawd S ^b  

^a MAYO CLINIC   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Antiretroviral agents; HIV; Integrase inhibitors; Ralteravir

Indexed keywords

ATAZANAVIR; CYTOCHROME P450; DARUNAVIR; EFAVIRENZ; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETRAVIRINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; TENOFOVIR; TIPRANAVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DNA INTEGRATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; FOOD DRUG INTERACTION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS REPLICATION;

EID: 44049098603     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Anderson MS, Wenning L, Moreau A, et al. 2007. Effect of raltegravir on the pharmacokinetics of oral contraceptives. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. September 17-20, 2007. Abstract A-1425.
2. Cooper D, Gatell J, Rockstroh J, et al. 2007. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, California. Abstracts 105aLB.
3. Craigie R. 2001. HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem, 276:23213-6.
4. DeJesus E, Cohen C, Elion R, et al. 2007. First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137). Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract TUPEB032.
5. Embrey MW, Wai JS, Funk TW, et al. 2005. A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg Med Chem Lett, 15:4550-4.
6. Espeseth AS, Felock P, Wolfe A, et al. 2000. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA, 97:11244-9.
7. Grinsztejn B, Nguyen B, Katlama C, et al. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet, 369:1261-9.
8. Hazuda D, Blau CU, Felock P, et al. 1999. Isolation and characterization of novel human immunodeficiency virus integrase inhibitors from fungal metabolites. Antivir Chem Chemother, 10:63-70.
9. Hazuda DJ, Anthony NJ, Gomez RP, et al. 2004. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci USA, 101:11233-8.
10. Hazuda DJ, Felock P, Witmer M, et al. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science, 287:646-50.
11. Hazuda DJ, Miller MD, Nguyen BY, et al. 2007. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase II study in patients with triple-class-resistant HIV-1 infection. Program and abstracts of the 16th International HIV Drug Resistance Workshop; June 12-16, 2007; Barbados, West Indies. Abstract 8.
12. Isentress prescribing information. Merck and Co., Iin., Whitehouse Station, NJ 08889, USA.
13. ISENTRESS™ (raltegravir) 400 mg for treatment of HIV (NDA 22-145) 2007. FDA Briefing Document. Accessed October 15, 2007.URL: http://www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007-4314b1-01-Merck.pdf.
14. Iwamoto M, Wenning LA, Liou SY, et al. 2006. Rifampin (RIF) modestly reduces plasma levels of MK-0518. 8th international congress on drug therapy in HIV infection, Glasgow. Nov 2006. Abstract 20061; p299.
15. Iwamoto M, Wenning LA, Petry AS et al. 2006. Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (PK) ofMK-0518. 46th Annual ICAAC Meeting. San Francisco, CA, 2006: Abstract 2006b; A-373.
16. Kassahun K, McIntosh I, Cui D, et al. 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the HIV-1 integrase enzyme. Drug Metab Dispos, 35:1657-63.
17. Kassahun K, McIntosh I, Hreniuk D, et al. 2006. Absorption, metabolism and excretion of MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, USA, Sept 27-30, 2006: abstract A-372.
18. Kumar P, Cooper D, Steigbigel R, et al. 2007. Efficacy of raltegravir, an HIV integrase inhibitor, in combination with regimens containing enfuvirtide, darunavir, or tipranavir in patients with triple-class resistant virus: combined results from Benchmrk-1 and Benchmrk-2. European AIDS Conference. October 24-27, 2007. Madrid. Abstract P7.2/06.
19. LaFemina RL, Schneider CL, Robbins HO, et al. 1992. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol, 66:7414-19.
20. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr, 43:509-15.
21. Markowitz M, Nguyen BY, Gotuzzo E, et al. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr, 46:125-33.
22. McColl DJ, Fransen S, Gupta S, et al. 2007. Resistance and cross-resistance to first-generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). Program and abstracts of the 16th International HIV Drug Resistance Workshop; June 12-16, 2007; Barbados, West Indies. Abstract 9.
23. Miller MD, Witmer MV, Stillmock KA, et al. 2006. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor. In: program and abstracts of XVI International AIDS Conference; 2006, Toronto.
24. Mistry G, Wenning L, Petry A, et al. 2007. Atazanavir modestly increases plasma levels of MK-0518. 4h International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sidney, Australia, 2007. Abstract number:1985.
25. Pais GCG, Zhang XC, Marchand C, et al. 2002. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J Med Chem, 45:3184-94.
26. Steigbigel R, Kumar P, Eron J, et al. 2007. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, California. Abstracts 105bLB.
27. Wenning LA, Friedman E, Kost JT, et al. 2006. Lack of significant drug interaction between MK-0518 and tenofovir disoproxil fumarate. 46th Annual ICAAC Meeting. San Francisco, CA, 2006: Abstract 2006b; A-375.
28. Wenning LA, Hanley H, Stone J, et al. 2006. Effect of tipranavir + ritonavir on pharmacokinetics of MK-0518. 46th Annual ICAAC Meeting. San Francisco, CA, 2006: Abstract 2006a; A-374.